Physician profile
Lan Mo
NPI 1760786388
$55,546.57
in general payments reported to CMS, 2019-2025
42 companies · $5,568 in 2025
The $5,568 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,823 · 2020: $13K · 2021: $7,034 · 2022: $8,925 · 2023: $6,654 · 2024: $6,953 · 2025: $5,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $5,632 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Education: $121 · Travel and Lodging: $36.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,885.00 |
| Food and Beverage | $5,632.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Education | $120.99 |
| Travel and Lodging | $36.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $16,586.53 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,382.88 | 2019-2025 | |
| Dova Pharmaceuticals | $5,930.00 | 2020-2021 | |
| Exelixis INC. | $5,697.55 | 2019-2025 | Cabometyx |
| Eisai INC. | $3,708.64 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,402.98 | 2019-2025 | Opdivo |
| Coherus Oncology, INC. | $2,700.00 | 2022 | |
| Eli Lilly and Company | $2,300.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,667.17 | 2021-2023 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $1,069.68 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Janssen Biotech, INC. | $731.55 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Beigene USA, INC. | $650.00 | 2021-2023 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $622.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $513.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $311.92 | 2019-2025 | Enhertu, Datroway, Vanflyta |
Show all 40 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Mo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.